Annual General Meeting 2024


June 24, 2024

Amsterdam

Past events

10th International mRNA Health Conference


November 8-10, 2022

Boston

Downloads

Berenberg and Goldman Sachs Eleventh German Corporate Conference


September 20, 2022

Munich

Downloads

Morgan Stanley 20th Annual Global Healthcare Conference


September 12, 2022

New York

Downloads

The JMP Securities Life Sciences Conference


June 15, 2022

New York

Downloads

Jefferies Healthcare Conference


June 9, 2022

New York

Downloads

UBS – 2022 Global Healthcare Conference


June 1, 2022

Virtual

Downloads

BofA Securities 2022 Healthcare Conference


May 10, 2022

Las Vegas

Downloads

Fourth Quarter and Full-Year 2021 Financial Results and Business Updates – Conference Call & Webcast


April 28, 2022

CureVac N.V. (Nasdaq: CVAC) has reported financial results, and provided business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022. On the same day, the company hosted a conference call and webcast.

Please find the corresponding press release and presentation slides below. An archived webcast will also be made available through the same link on the CureVac website shortly.

15th Kempen Life Sciences Conference


April 20, 2022

Amsterdam, The Netherlands

Downloads

Links

Berenberg European Conference


December 8, 2021

Virtual

Conference Call & Webcast: Third Quarter and First Nine Months 2021 Financial Results and Business Updates


November 19, 2021

CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the third quarter and first nine months of 2021 on Friday, November 19, 2021. The company hosted a conference call and webcast on the same day at 2:00 p.m. CET / 08:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript and the archived webcast below.

SITC 2021 Conference


November 10 - 14, 2021

Washington, D.C., & virtually

9th International mRNA Health Conference


November 09 - 10, 2021

Hybrid event on-site in Berlin, Germany, and online via virtual platform

Conference Call & Webcast: Focus Shift to Second-Generation mRNA Technology


October 12, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

The company hosted a conference call and webcast on the same day at 03:00 p.m. CEST / 09:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript as well as an archived webcast below.

Press Conference: Focus Shift to Second-Generation mRNA Technology (German language)


October 12, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

The company hosted a German speaking press conference on the same day at 02:00 p.m. CEST / 08:00 a.m. EST.

Please find the corresponding press release, presentation slides and archived webcast below.

Downloads

Links